This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLinked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLinkEN - EnglishSelect a languageLanguagesEN - EnglishFR - FrançiasSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page
Administration and Storage Choosing ReFacto AFChoosing ReFacto AFChoosing ReFacto AFPersonalised dosing On-Demand Use

Menu

Close

Product InformationProduct InformationLaboratory StandardEfficacy & SafetyAdministration & StorageSupport & ResourcesSupport & ResourcesMaterialsVideosOrdering ReFacto AFContact Us

For ReFacto AF® (moroctocog alfa) Prescribing Information for Great Britain and Northern Ireland click here.
Adverse event reporting information can be found at the bottom of the page.

Administration & StorageAdministration

ReFacto AF® can be reconstituted and administered using our R2 or FuseNGo devices.

Administration: intravenous infusion1

  • Administered by intravenous infusion over several minutes after reconstitution of the lyophilised powder for injection with sodium chloride 9 mg/mL (0.9%) solution for injection (provided).1 The rate of administration should be determined by the patient's comfort level.1
  • ReFacto AF can be administered with two types of devices: R2 reconstitution device (powder and solvent for solution for injection)2, and FuseNGo all in one reconstitution device (powder and solvent for solution for injection in pre-filled syringe).3
  • For further support, refer to the Refacto AF Infusion mat step-by-step guide. Download the R2 and FuseNGo Infusion mats here. 
Request printed copies or other materials through our Contact Us page.Storage

How to store ReFacto AF®:

  • Store and transport refrigerated (2°C - 8°C).1
  • Do not freeze.1
  • Keep the product in the outer carton to protect it from light.1
  • ReFacto AF® has a shelf life of 3 years.1
  • The product may be removed from refrigerated storage for one single period of maximum 3 months at room temperature (up to 25°C).1
  • At the end of this period of room temperature storage, the product must not be returned to refrigerated storage, but is to be used or discarded.1

After reconstitution:
  • Chemical and physical in-use stability has been demonstrated for 3 hours at temperatures up to 25°C.1
  • The product does not contain a preservative.1
  • The reconstituted product should be used immediately, or within 3 hours after reconstitution.1
Explore MorePersonalised Dosing

Access information to help determine adequate dosing for your patient and improve their peak control.

Find out moreLoadingMaterials

Access resources and additional information that aim to support you and your patients.

Find out moreLoadingContact Us

Contact us for more information on ReFacto AF and download our FAQ for supply and stock related queries.

Find out more Loading

References

ReFacto AF® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.ReFacto AF® powder and solvent for solution for injection Patient Information LeafletReFacto AF® powder and solvent for solution for injection in pre-filled syringe Patient Information Leaflet
PP-REF-GBR-0352. July 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​
​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​